Foamix Pharmaceuticals Second Quarter Financial Results Conference Call & Webcast Scheduled for Wednesday, August 10
Conference Call & Webcast
About Foamix Pharmaceuticals Ltd.
Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Our clinical stage product candidates include FMX101, our novel minocycline foam for the treatment of moderate-to-severe acne, now in Phase III, FMX 103 for the treatment of rosacea now in Phase II, FMX102 for the treatment of impetigo, and FDX104, our doxycycline foam for the management of acne-like rash, induced by EGFRI anticancer drugs.
In addition, we have development and license agreements relating to our technology with various pharmaceutical companies including
Ilan Hadar, CFO Foamix Pharmaceuticals Ltd.+972-8-9316233 Ilan.firstname.lastname@example.org US Investor Relations Michael Rice LifeSci Advisors, LLC646-597-6979 email@example.com